Related Experiment Video
Updated: Mar 29, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Molecular Mechanisms of Cardiac Fibrosis: A Pathologist's Perspective
Andrea Marzullo1, Cecilia Salzillo1,2
1Department of Precision and Regenerative Medicine and Ionian Area, Pathology Unit, University of Bari "Aldo Moro", 70124 Bari, Italy.
Insights
Cardiac fibrosis, a key factor in heart failure, involves fibroblast activation and extracellular matrix remodeling. Understanding these molecular pathways is crucial for developing new antifibrotic therapies.
Area of Science:
- Pathology
- Cardiovascular Biology
- Molecular Medicine
Background:
- Cardiac fibrosis is a common endpoint for various heart conditions, leading to structural changes, diastolic dysfunction, and heart failure.
- Pathologically, fibrotic remodeling manifests as interstitial, perivascular, and replacement patterns, reflecting underlying cellular and molecular processes.
- Fibroblast activation into myofibroblasts is central, driven by profibrotic pathways like TGF-β/SMAD, Wnt/β-catenin, and Hippo/YAP/TAZ.
Purpose of the Study:
- To integrate molecular signaling mechanisms with morphologic evidence of cardiac fibrosis.
- To highlight the pathologist's role in linking molecular insights to diagnostic interpretation.
- To provide a foundation for developing novel antifibrotic therapies.
Main Methods:
- Review of molecular signaling cascades (e.g., TGF-β, Wnt, Hippo pathways) involved in fibroblast activation.
- Analysis of neurohumoral mediators (angiotensin II, aldosterone) and epigenetic modulators (n-c RNAs).
- Correlation of molecular events with histopathological findings (collagen deposition, α-SMA expression, ECM cross-linking) using immunohistochemistry and digital morphometry.
Main Results:
- Profibrotic signaling pathways (TGF-β/SMAD, Wnt/β-catenin, Hippo/YAP/TAZ) drive cardiac fibroblast activation.
- Neurohumoral factors and epigenetic regulators amplify extracellular matrix synthesis and perpetuate fibrosis.
- Histopathological features like collagen deposition and α-SMA expression are direct correlates of these molecular mechanisms.
Conclusions:
- Cardiac fibrosis results from complex molecular signaling driving fibroblast activation and matrix remodeling.
- Pathologists play a vital role in interpreting fibrotic changes by connecting molecular mechanisms to diagnostic findings.
- Targeting key molecular nodes in fibroblast activation and matrix remodeling offers potential for new antifibrotic treatments.
Abstract:
Cardiac fibrosis represents a final common pathway in a wide range of cardiac disorders, leading to structural remodeling, diastolic dysfunction, and heart failure. From a pathologist's viewpoint, fibrotic remodeling displays distinctive morphologic patterns such as interstitial, perivascular, and replacement fibrosis, which mirror specific cellular and molecular mechanisms. Central to this process is the activation of cardiac fibroblasts into myofibroblasts, driven by profibrotic signaling cascades such as transforming growth factor beta (TGF-β)/mothers against decapentaplegic homolog proteins (SMAD), Wingless/Integrated signaling pathway (Wnt)/βeta-catenin, and Hippo-Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) pathways. Neurohumoral mediators, including angiotensin II and aldosterone, further amplify extracellular matrix synthesis and tissue stiffness. Epigenetic modulators and non-coding RNAs (n-c RNAs) orchestrate transcriptional programs that perpetuate fibroblast activation. Histopathological correlates of these molecular events, collagen deposition, alpha-smooth muscle actin (α-SMA) expression, and extracellular matrix (ECM) cross-linking, can be demonstrated through immunohistochemistry and digital morphometry. This review integrates molecular signaling and morphologic evidence to delineate the mechanisms of cardiac fibrosis, emphasizing the pathologist's role as a link between molecular insight and diagnostic interpretation. Understanding these intertwined processes provides the foundation for novel antifibrotic therapies targeting key molecular nodes of fibroblast activation and matrix remodeling.
More Related Videos
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Myocarditis I: Introduction
Rheumatic Heart Disease I: Introduction

